Calcium renal lithiasis
metabolic diagnosis and medical treatment
Keywords:
Kidney calculi, Therapeutics, Metabolism, Diagnosis, Pharmacy, CalciumAbstract
Calcium renal lithiasis is a frequent condition that affects the worldwide population and has a high recurrence rate. Different metabolic changes may trigger the onset of calcium stone disorders, such as hypercalciuria, hyperoxaluria, hyperuricosuria, hypocitraturia and others. There are also other very prevalent disorders that are associated with calcium calculi, such as arterial hypertension, obesity and loss of bone mineral density. A correct diagnosis needs to be obtained through examining the serum and urinary parameters of mineral metabolism in order to carry out adequate prevention and treatment of this condition. Once the metabolic diagnosis is known, it is possible to establish dietary and pharmacological treatment that may enable monitoring of the disease and prevent recurrence of stone formation. Some advances in treating this pathological condition have been made, and these include use of sodium alendronate in patients with calcium renal lithiasis and osteopenia/osteoporosis, or use of a combination of a thiazide with a bisphosphonate. In summary, calcium renal lithiasis often requires multidrug treatment with strict control and follow-up of patients.
Downloads
References
Alapont Pérez FM, Gálvez Calderón J, Varea Herrero J, et al. Epidemiología de la litiasis urinaria [Epidemiology of urinary lithiasis]. Actas Urol Esp. 2001;25(5):341-9.
Bihl G, Meyers A. Recurrent renal stone disease-advances in pathogenesis and clinical management. Lancet. 2001;358(9282):651-6.
Evan AP. Physiopathology and etiology of stone formation in the kidney and the urinary tract. Pediatr Nephrol. 2010;25(5):831-41
Soucie JM, Coates RJ, McClellan W, Austin H, Thun M. Relation between geographic variability in kidney stones prevalence and risk factors for stones. Am J Epidemiol. 1996;143(5):487-95.
Arrabal Martín M, Fernández Rodríguez A, Arrabal Polo MA, Ruíz García MJ, Zuluaga Gómez A. Estudio de factores físico-químicos en pacientes con litiasis renal. [Study of the physical-chemical factors in patients with renal lithiasis]. Arch Esp Urol. 2006;59(6):583-94.
Hermida Pérez JA, Pérez Palmes MP, Loro Ferrer JF, Ochoa Urdangarain O, Buduen Nuñez A. Cólico nefrítico en el servicio de urgencias. Estudio epidemiológico, diagnostico y etiopatogénico [Renal colic at emergency departments: Epidemiologic, diagnostic andetiopathogenic study]. Arch Esp Urol. 2010;63(3):173-87.
Eliahou R, Hidas G, Duvdevani M, Sosna J. Determination of renal stone composition with dual-energy computed tomography: an emerging application. Semin Ultrasound CT MR. 2010;31(4):315-20.
Evan A, Lingeman J, Coe FL, Worcester E. Randall’s plaque: pathogenesis and role in calcium oxalate nephrolithiasis. Kidney Int. 2006;69(8):1313-8.
Evan AP, Lingeman JE, Coe FL, Worcester EM. Role of interstitial apatite plaque in the pathogenesis of the common calcium oxalate stone. Semin Nephrol. 2008;28(2):111-9.
Matlaga BR, Coe FL, Evan AP, Lingeman JE. The role of Randall’s plaques in the pathogenesis of calcium stones. J Urol. 2007;177(1):31-8.
Grases F, Costa-Bauzá A, Gomila I, Conte A. Origin and types of calcium oxalate monohydrate papillary renal calculi. Urology. 2010;76(6):1339-45.
Tsujihata M. Mechanism of calcium oxalate renal stone formation and renal tubular cell injury. Int J Urol. 2008;15(2):115-20.
Worcester EM, Coe FL. Clinical practice. Calcium kidney stones. N Engl J Med. 2010;363(10):954-63.
Lancina Martín JA. Litiasis urinaria. Presente y future. Actas Urológicas Españolas. 2005;29(4):339-44. Available from: http://www.elsevier.es/ es/revistas/actas-urologicas-españolas-292/litiasis-urinaria-presente- futuro-13144104-editoriales-2005. Accessed in 2012 (Aug 16).
Chandhoke PJ. Evaluación del formador recurrente de cálculos. Urol Clin N Am. 2007;34:315-22. Available from: http://www.elsevier.es/ sites/default/files/elsevier/pdf/507/507v34n03a13122979pdf001. pdf. Accessed in 2012 (Aug 16).
Areses Trapote R, Urbieta Garagorri MA, Ubetagoyena Arrieta M, Mingo Monge T, Arruebarrena Lizarraga D. Evaluación de la enfermedad renal litiásica. Estudio metabólico [Evaluation of renal stone disease: metabolic study]. An Pediatr (Barc). 2004;61(5):418-27.
Parmar MS. Kidney stones. BMJ. 2004;328(7453):1420-4.
Sakhaee K. Recent advances in the pathophysiology of nephrolithiasis. Kidney Int. 2009;75(6):585-95.
Park S, Pearle MS. Fisiopatología y tratamiento de los cálculos de calico. Urol Clin N Am. 2007;34:323-34. Available from: http://www. elsevier.es/sites/default/files/elsevier/pdf/507/507v34n03a13122980 pdf001.pdf. Accessed in 2012 (Aug 16).
Arrabal-Polo MA, Arrabal-Martin M, de Haro-Munoz T, et al. Mineral density and bone remodelling markers in patients with calcium lithiasis. BJU Int. 2011;108(11):1903-8; discussion 1908.
Yuen JW, Gohel MD, Poon NW, et al. The initial and subsequent inflammatory events during calcium oxalate lithiasis. Clin Chim Acta. 2010;411(15-16):1018-26.
Frick KK, Bushisnky DA. Molecular mechanisms of primary hypercalciuria. J Am Soc Nephrol. 2003;14(4):1082-95.
Stechman MJ, Loh NY, Thakker RV. Genetic causes of hypercalciuric nephrolithiasis. Pediatr Nephrol. 2009;24(12):2321-32.
Worcester EM, Coe FL. New insights into the pathogenesis of idiopathic hypercalciuria. Semin Nephrol. 2008;28(2):120-32.
Ossandón Salas E, Storme Cabrera O, Ledesma R, et al. Resultados del estudio metabólico en 54 pacientes con urolitiasis de alto riesgo de recurrencia [Metabolic study results of 54 patients with high risk of recurrent urolithiasis]. Actas Urol Esp. 2009;33(4):429-32.
Pak CY, Britton F, Peterson R, et al. Ambulatory evaluation of nephrolithiasis. Classification, clinical presentation and diagnostic criteria. Am J Med. 1980;69(1):19-30.
Reina Ruiz CM, Conde Sánchez JM, Domínguez Domínguez M, Espinosa Olmedo J, García Pérez M. Papel del fosfato en la litiasis cálcica recidivante. Una visión actual [Role of phosphate in recurrent calcium lithiasis: The recurrent concept]. Arch Esp Urol. 2001;54:1029-
Available from: http://pesquisa.bvsalud.org/regional/resources/ ibc-27478. Accessed in 2012 (Aug 16).
Hoppe B, Beck BB, Milliner DS. The primary hyperoxalurias. Kidney Int. 2009;75(12):1264-71.
Hoppe B, Langman CB. A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria. Pediatr Nephrol. 2003;18(10):986-91.
Siva S, Barrack ER, Reddy GP, et al. A critical analysis of the role of gut Oxalobacter formigenes in oxalate stone disease. BJU Int. 2008;103(1):18-21.
Annuk M, Backman U, Holmgren K, Vessby B. Urinary calculi and jejunoileal bypass operation. A long-term follow-up. Scand J Urol Nephrol. 1998;32(3):177-80.
Schwille PO, Schmiedl A, Herrmann U, et al. Magnesium, citrate, magnesium citrate and magnesium-alkali citrate as modulators of calcium oxalate crystallization in urine: observations in patients with recurrent idiopathic calcium urolithiasis. Urol Res. 1999;27(2):117-26.
Bek-Jensen H, Fornander AM, Nilsson MA, Tiselius HG. Is citrate an inhibitor of calcium oxalate crystal growth in high concentrations of urine? Urol Res. 1996;24(2):67-71
Tiselius HG, Fornander AM, Nilsson MA. The effects of citrate and urine on calcium oxalate crystal aggregation. Urol Res. 1993;21(5):363-6.
Lewandowski S, Rodgers AL. Idiopathic calcium oxalate urolithiasis: risk factors and conservative treatment. Clin Chim Acta. 2004; 345(1-2):17-34.
Lancina Martín JA, Rodríguez-Rivera García J, Novás Castro S, et al. Factores de riesgo metabólico en urolitiasis cálcica según el sexo y edad de los pacientes. Actas Urológicas Españolas. 2002;26(2):111-20. Available from: http://www.elsevier.es/en/node/2079359. Accessed in 2012 (Aug 16).
Grases F, Sanchis P, Perelló J, Costa-Bauzá A. Role of uric acid in different types of calcium oxalate renal calculi. Int J Urol. 2006;13(3):252-6.
Madore F, Stampfer MJ, Rimm EB, Curhan GC. Nephrolithiasis and risk of hypertension. Am J Hypertens. 1998;11(1 Pt 1):46-53.
Madore F, Stampfer MJ, Willet WC, Speizer FE, Curhan GC. Nephrolithiasis and risk of hypertension in women. Am J Kidney Dis. 1998;32(5):802-7.
Blackwood AM, Sagnella GA, Cook DG, Cappuccio FP. Urinary calcium excretion, sodium intake and blood pressure in a multi-ethnic population: results of the Wandsworth Heart and Stroke Study. J Hum Hypertens. 2001;15(4):229-37.
Cirillo M, Ciacci C, Laurénzi M, et al. Salt intake, urinary sodium, and hypercalciuria. Miner Electrolyte Metab. 1997;23(3-6):265-8.
Daudon M, Lacour B, Jungers P. Influence of body size on urinary stone composition in men and women. Urol Res. 2006;34(3):193-9.
Asplin JR, Coe FL. Hyperoxaluria in kidney stone formers treated with modern bariatric surgery. J Urol. 2007;177(2):565-9.
Zerwekh JE. Bone disease and idiopathic hypercalciuria. Semin Nephrol. 2008;28(2):133-42.
Reed BY, Gitomer WL Heller HJ, et al. Identification and characterization of a gene with base substitutions associated with the absorptive hypercalciuria phenotype and low spinal bone density. J Clin Endocrinol Metab. 2002;87(4):1476-85.
Gomes SA, dos Reis LM, Noronha IL, Jorgetti V, Heilberg IP. RANKL is a mediator of bone resorption in idiopathic hypercalciuria. Clin J Am Soc Nephrol. 2008;3(5):1446-52.
Sakhaee K, Maalouf NM, Kumar R, Pasch A, Moe OW. Nephrolithiasis- associated bone disease: pathogenesis and treatment options. Kidney Int. 2011;79(4):393-403.
Hall PM. Nephrolithiasis: treatment, causes, and prevention. Cleve Clin J Med. 2009;76(10):583-91.
Valle Díaz de la Guardia F, Arrabal Martín M, Arrabal Polo MA, et al. Litiasis renal en pacientes con hiperparatiroidismo primario. Evolución y tratamiento [Renal lithiasis in patients with primary hyperparathyroidism. Evolution and treatment]. Arch Esp Urol. 2010;63(1):32-40.
Arrabal Martín M, Valle Díaz de la Guardia F, Jiménez Pacheco A, et al. Tratamiento de la litiasis renal con bifosfonatos [The treatment of renal lithiasis with biphosphonates]. Arch Esp Urol. 2007;60(7):745-54.
Pak CY, Sakhaee K, Moe O, et al. Biochemical profile of stone-forming patients with diabetes mellitus. Urology. 2003;61(3):523-7.
Zimmerer T, Weiss C, Hammes HP, et al. Evaluation of urolithiasis: a link between stone formation and diabetes mellitus? Urol Int. 2009;82(3):350-5.
Tiselius HG; Advisory Board of European Urolithiasis Research and EAU Health Care Office Working Party for Lithiasis. Possibilities for preventing recurrent calcium stone formation: principles for the metabolic evaluation of patients with calcium stone disease. BJU Int. 2001;88(2):158-68.
Straub M, Hautmann RE. Developments in stone prevention. Curr Opin Urol. 2005;15(2):119-26.
Grases F, Costa-Bauza A, Prieto RM. Renal lithiasis and nutrition. Nutr J. 2006;5:23.
Fink HA, Akornor JW, Garimella PS, et al. Diet, fluid, or supplements for secondary prevention of nephrolithiasis: a systematic review and meta-analysis of randomized trials. Eur Urol. 2009;56(1):72-80.
Pietrow PR, Karellas ME. Medical management of common urinary calculi. Am Fam Physician. 2006;74(1):86-94.
Jiménez Verdejo A, Arrabal Martín M, Miján Ortiz JL, et al. Efecto del citrato potásico en la profilaxis de la litiasis urinaria [Effect of potassium citrate in the prophylaxis of urinary lithiasis]. Arch Esp Urol. 2001;54(9):1036-46.
Fernández-Rodríguez A, Arrabal-Martín M, García-Ruiz MJ, et al. Papel de las tiazidas en la profilaxis de la litiasis cálcica recidivante [The role of thiazides in the prophylaxis of recurrent calcium lithiasis]. Actas Urol Esp. 2006;30(3):305-9.
Arrabal-Martín M, Fernández-Rodríguez A, Arrabal-Polo MA, García- Ruiz MJ, Zuluaga-Gómez A. Extracorporeal renal lithotripsy: evolution of residual lithiasis treated with thiazides. Urology. 2006;68(5):956-9.
Arrabal-Polo MA, Arrabal-Martin M, Zuluaga-Gomez A. Alendronate and resorptive hypercalciuria [Alendronate and resorptive hypercalciuria]. Med Clin (Barc). 2011;137(7):333.
Bushinsky DA, Neumann KJ, Asplin J, Krieger NS. Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats. Kidney Int. 1999;55(1):234-43.
Giusti A, Barone A, Pioli G, et al. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments. Nephrol Dial Transplant. 2009;24(5):1472-7.
